Expertise in
3
conditions

Emmanuelle Tavernier

CHU Saint Etienne
Saint-etienne-de-valoux, FR 
Expertise in
3
conditions
CHU Saint Etienne
Saint-etienne-de-valoux, FR 

Overview

Emmanuelle Tavernier practices practicing medicine in Saint-etienne-de-valoux, France.

Ms. Tavernier is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Leukemia, Hepatic Venoocclusive Disease with Immunodeficiency, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 10 clinical trials.

Gender

Female

Locations

CHU Saint Etienne
Saint-etienne-de-valoux, France
Other Locations
St Priest En Jarez, Sete, France
Saint-priest-la-vetre, France
CH de Valence
Valence, France
Saint Étienne, France
Clermont-ferrand, France
Hôpital St Louis, APHP
Paris, France
Hôtel Dieu CHU de Nantes
Nantes, France
Lyon, 69675, France
Grenoble, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Administration of Fibrinogen Concentrate for Refractory Bleeding in Hematological Patients With Intensive Chemotherapy-induced Thrombocytopenia - Analysis Using Viscoelastic Haemostatic Assay (FORMAT)
Administration of Fibrinogen Concentrate for Refractory Bleeding in Hematological Patients With Intensive Chemotherapy-induced Thrombocytopenia - Analysis Using Viscoelastic Haemostatic Assay (FORMAT)
Enrollment Status: Terminated
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: Fibrinogen Concentrate Human
Study Phase: Phase 2
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life: REACT Study
RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life: REACT Study
Enrollment Status: Terminated
Publish Date: March 04, 2024
Intervention Type: Other
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (COSMOS)
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (COSMOS)
Enrollment Status: Terminated
Publish Date: May 06, 2023
Intervention Type: Other
Study of Thromboelastography During Tranexamic Acid Treatment in Preventing Bleeding in Patients With Haematological Malignancies Presenting Severe Thrombocytopenia (TTRAP-bleeding)
Study of Thromboelastography During Tranexamic Acid Treatment in Preventing Bleeding in Patients With Haematological Malignancies Presenting Severe Thrombocytopenia (TTRAP-bleeding)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tranexamic acid
Study Phase: Phase 2
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Other
CPX-351 in Higher Risk Myelodysplastic Syndromes: a Phase I/ II Study as First Line or After Hypomethylating-agents Failure
CPX-351 in Higher Risk Myelodysplastic Syndromes: a Phase I/ II Study as First Line or After Hypomethylating-agents Failure
Enrollment Status: Completed
Publish Date: July 07, 2022
Intervention Type: Drug
Study Drug: CPX-351
Study Phase: Phase 1/Phase 2
SPPLAASH Study : a Randomized Study Aiming at Evaluating the Incidence of Post Lumbar Puncture Headache (PLPH) With the Use of Atraumatic Needles in Hematology
SPPLAASH Study : a Randomized Study Aiming at Evaluating the Incidence of Post Lumbar Puncture Headache (PLPH) With the Use of Atraumatic Needles in Hematology
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Device
Study Phase: Not Applicable
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Enrollment Status: Completed
Publish Date: January 29, 2020
Intervention Type: Device
Study Phase: Phase 3
Effects of Injection Tinzaparin Prophylactic Dose (4,500 IU Anti-Xa) on Thrombin Generation in Patients With Multiple Myeloma, Lymphoma Patients and Patients Hospitalized for an Acute Medical Condition.
Effects of Injection Tinzaparin Prophylactic Dose (4,500 IU Anti-Xa) on Thrombin Generation in Patients With Multiple Myeloma, Lymphoma Patients and Patients Hospitalized for an Acute Medical Condition.
Enrollment Status: Completed
Publish Date: May 11, 2017
Intervention Type: Drug, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

54 Total Publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Frequently Asked Questions about Emmanuelle Tavernier

Is Emmanuelle Tavernier a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Emmanuelle Tavernier is classified as an Advanced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emmanuelle Tavernier participate in research or clinical trials?

Yes. Emmanuelle Tavernier has published 54 articles and abstracts on conditions like Leukemia. You can view a list of Emmanuelle Tavernier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tavernier's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile